Results 141 to 150 of about 3,069,445 (313)

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Review of Evidence-Based Clinical and Experimental Research on the Use of Acupuncture and Chinese Herbal Medicine for the Treatment or Adjunct Treatment of Cancer [PDF]

, 2017
Huisheng Xie, Betsy Hershey, Aituan Ma
openalex   +1 more source

Supplementary Figure 3 from MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research

, 2023
Wendy Chang, Andrew S. Brohl, Rajesh Patidar, Sivasish Sindiri, Jack F. Shern, Jun S. Wei, Young Song, Marielle E. Yohe, Berkley E. Gryder, Shile Zhang, Jean Jenkins, Nityashree Shivaprasad, Xinyu Wen, Thomas Badgett, Markku Miettinen, Kip R. Hartman, James C. League-Pascual, Toby N. Trahair, Brigitte C. Widemann, Melinda S. Merchant, Rosandra N. Kaplan, Jimmy Lin, Javed Khan   +22 more
openalex   +1 more source

Cancer Research UK [PDF]

Nature Cell Biology, 2002
openaire   +2 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

COMPUTER-AIDED DRUG DESIGN AND ITS APPLICATIONS IN CANCER RESEARCH: A REVIEW

Krishno Chandra, Shweta Sharma, MONIKA AHLAWAT, Suvarcha Chauhan, Ashok Sharma   +4 more
openalex   +2 more sources

Research of Clinical and Paraclinical Characteristics of Laryngeal Cancer of National Otorhinolaryngology Hospital of Vietnam from 11/2022 to 4/2023

, 2023
Ha Xuan Nghia, Nguyen Tuan Sơn, Dao Dinh Linh, Le Thi Nhung, Pham Duc Duy, Nguyen Trung Duy   +5 more
openalex   +2 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

YW1-06 Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells (Young Urologist Research Workshop)

, 2004
Makoto Sumitomo
openalex   +2 more sources

Metformin and Prostate Cancer: A New Era of s Prostate Cancer Research [PDF]

, 2018
Bader Abdelmaksoud
openalex   +1 more source